Publications by authors named "Mark Fallick"

Claim this Profile
A
Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.
Nadine A Friedrich, Jessica L Janes, Joshua Parrish, Amanda M De Hoedt, Janis Pruett, Mark Fallick

Prostate Cancer Prostatic Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Prostate Cancer-Related Symptoms and Toxicities Following Stereotactic Body Radiation Therapy: Implications for Future Radionuclide Therapy.
Diya Kallam, Kelly Gaudian, Ryan Collins, Zoya Zwart, Min Ji Koh, Mark Fallick

Cureus· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer.
Kelly Gaudian, Min Jung Koh, Min Ji Koh, Ryan R Collins, Shaine Eden, Mark Fallick

Front Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.
Nadine Friedrich, Nadine Friedrich, Jessica Janes, Joshua Parrish, Amanda De Hoedt, Mark Fallick

Res Sq· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Ronald Tutrone, Fred Saad, Daniel J George, Bertrand Tombal, James L Bailen, Mark Fallick

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Novel Patient-Reported Outcome Measure to Assess Symptoms and Impacts of Androgen Deprivation Therapy for Advanced Prostate Cancer.
Ashley Ross, Kelsie Brewer, Stacie Hudgens, Bruce Brown, Mark Fallick

Adv Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
Daniel E Spratt, Daniel J George, Neal D Shore, Michael S Cookson, Daniel R Saltzstein, Mark Fallick

JAMA Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Daniel E Spratt, Tanya Dorff, Rana R McKay, Benjamin H Lowentritt, Mark Fallick

Future Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of Cardiovascular Events in Patients With Prostate Cancer and Treated With Androgen Deprivation Therapy.
Benjamin Lowentritt, Mark Fallick, Janis Pruett, Tao Jiang, Eddie Li

Urol Pract· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Neal D Shore, Bryan A Mehlhaff, Michael S Cookson, Daniel R Saltzstein, Ronald Tutrone, Mark Fallick

Adv Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
Lindsey Gallagher, Jerry Xiao, Jessica Hsueh, Sarthak Shah, Malika Danner, Mark Fallick

Front Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis